CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property associated with the world’s first minimally invasively-delivered soft robotic heart device to support heart function. The company also announced that it has become a resident at Johnson & Johnson Innovation, JLABS at the Texas Medical Center (JLABS @ TMC). This residency follows a $6.1 million funding from the Wellcome Trust, details of which have not been disclosed.
